Scientific Publications Citizens of Science

In our quest to invent life-transforming medicines for people with serious diseases, we encourage our colleagues to publish their research in leading scientific journals.

The links on this page are not affiliated with Regeneron Pharmaceuticals, Inc. Links to sites outside of Regeneron are provided as a resource to the viewer. Regeneron accepts no responsibility for the content of linked sites.

Featured Publications
Genetics
Rare coding variants in CHRNB2 reduce the likelihood of smoking

Published in Nat Genet. 2023 Jun 12. doi: 10.1038/s41588-023-01417-8.

A large meta-analysis identifies genes associated with anterior uveitis

Published in Nature Communications (2023) 14:1 Article Number: 7300. Date of Publication: 1 Dec 2023

Multi-trait analysis characterizes the genetics of thyroid function and identifies causal associations with clinical implications

Published in Nat Commun. 2024 Jan 30;15(1):888. doi: 10.1038/s41467-024-44701-9.

Immunology & Inflammation
TRAPnSeq allows high-throughput profiling of antigen-specific antibody-secreting cells

Published in Cell Rep Methods. 2023 Jul 7;3(7):100522. doi: 10.1016/j.crmeth.2023.100522. eCollection 2023 Jul 24

A therapeutic strategy to target distinct sources of IgE and durably reverse allergy

Published in Sci Transl Med. 2023 Dec 13;15(726):eadf9561. doi: 10.1126/scitranslmed.adf9561. Epub 2023 Dec 13

Obesity, Muscle & Metabolism
A cellular and molecular spatial atlas of dystrophic muscle

Published in Proc Natl Acad Sci U S A. 2023 Jul 18;120(29):e2221249120. doi: 10.1073/pnas.2221249120. Epub 2023 Jul 6

Activin E-ACVR1C cross talk controls energy storage via suppression of adipose lipolysis in mice

Published in Proc Natl Acad Sci U S A. 2023 Aug 8;120(32):e2309967120. doi: 10.1073/pnas.2309967120. Epub 2023 Jul 31

Preclinical, randomized phase 1, and compassionate use evaluation of REGN4461, a leptin receptor agonist antibody for leptin deficiency

Published in Sci Transl Med. 2023 Nov 22;15(723):eadd4897. doi: 10.1126/scitranslmed.add4897. Epub 2023 Nov 22

Technology
Structural analysis of cancer-relevant TCR-CD3 and peptide-MHC complexes by cryoEM

Published in Nat Commun. 2023 Apr 26;14(1):2401. doi: 10.1038/s41467-023-37532-7

Aging
Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial

Published in JAMA Ophthalmol. 2023 Aug 3. doi: 10.1001/jamaophthalmol.2023.2421. Online ahead of print

General Medicine
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration

Published in Nat Commun. 2023 Jun 17;14(1):3605. doi: 10.1038/s41467-023-39292-w

Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials

Published in Cancer Med. 2023 Jul 17. doi: 10.1002/cam4.6310.

Immunology & Inflammation
Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3

Published in Cancer. 2023 May 8. doi: 10.1002/cncr.34687

Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts

Published in N Engl J Med. 2023 May 21. doi: 10.1056/NEJMoa2303951

Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Published in Lancet Gastroenterol Hepatol. 2023 Aug 31:S2468-1253(23)00204-2. doi: 10.1016/S2468-1253(23)00204-2.

Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age

Published in N Engl J Med. 2024 Jun 27;390(24):2239-2251. doi: 10.1056/NEJMoa2312282.

Obesity, Muscle & Metabolism
Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia

Published in Circulation. 2023 Oct 20. doi: 10.1161/CIRCULATIONAHA.123.065529. Online ahead of print

Back
to top